William E. Rote

Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys

Thomas W. Geisbert, Lisa E. Hensley, Peter B. Jahrling et al. · The Lancet · 2003 · 381 citations · Full text

Rhesus Monkeys, Pathogenesis, Viral Pathogenesis +10

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Tissue factor/factor VIIa inhibitors block angiogenesis and tumor growth through a nonhemostatic mechanism.

Todd Hembrough, Glenn M. Swartz, Adonia E. Papathanassiu et al. · PubMed · 2003 · 197 citations

Immunology, Tumor Biology, Thrombosis +19

Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement

Agnes Lee, Giancarlo Agnelli, Harry Büller et al. · Circulation · 2001 · 166 citations